SCHEMBL727359

SCHEMBL727359

Clc1cc(Cl)c(Cl)cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29449468 1.00
SCHEMBL32681746 0.97 GABRP (0.33)
Formic Acid SCHEMBL27876421 0.85 KMT2A (0.34)
SCHEMBL28307383 0.78 HPGD (0.33)
SCHEMBL473692 0.75 KCNQ3 (0.31)
SCHEMBL30528380 0.75 KCNQ3 (0.31)
SCHEMBL16997464 0.75
SCHEMBL191637 0.75
SCHEMBL656692 0.75
SCHEMBL6307027 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110117251-B Preparation method of 4, 5-dichloro-2-hydroxypyridine 安庆睿升医药科技有限公司 2021-12-10 CN claimed
CN-110117251-A The preparation method of the chloro- 2 hydroxy pyrimidine of 4,5- bis- 上海睿升化工科技有限公司 2019-08-13 CN claimed
EP-4262788-B1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2026-01-21 EP disclosed
EP-4565323-A1 AROMATIC COMPOUNDS FOR USE AS PROTEIN PHOSPHATASE 2A (PP2A) MODULATORS Rappta Therapeutics Oy (FI) 2025-06-11 EP disclosed
EP-4486453-A1 BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2025-01-08 EP disclosed
EP-4446320-A1 NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Oncobix Co., Ltd. (KR) 2024-10-16 EP disclosed
US-20240294550-A1 8-OXA-3-AZABICYCLO[3.2.1]OCTANE COMPOUNDS OR SALT THEREOF, AND PREPARATION METHOD AND USE THEREOF LITTDD MEDICINES LTD (CN) 2024-09-05 US disclosed
CN-118355012-A Novel heterocyclic substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect and pharmaceutical composition containing the same 昂科比克斯有限公司 2024-07-16 CN disclosed
CN-113227071-B Amide-substituted heterocyclic compounds for the treatment of disorders associated with modulation of IL-12, IL-23 and/or IFN-alpha 百时美施贵宝公司 2024-06-25 CN disclosed
EP-4378943-A1 8-OXO-3-AZABICYCLO[3.2.1]OCTANE COMPOUND OR SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF Littdd Medicines Ltd (CN) 2024-06-05 EP disclosed
EP-3630291-B9 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 CANCER RESEARCH TECH LTD (GB) 2024-05-29 EP disclosed
US-20120165519-A1 Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors CEPHALON, INC. (US) 2012-06-28 US disclosed
US-20120165519-A1 Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors CEPHALON, INC. (US) 2012-06-28 US disclosed
EP-2421850-A1 3 -AZABICYCLO [4.1.0]HEPTANES USED AS OREXIN ANTAGONISTS Glaxo Group Limited (GB) 2012-02-29 EP disclosed
US-20120040991-A1 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2012-02-16 US disclosed
US-20120040991-A1 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2012-02-16 US disclosed
WO-2010122151-A1 3 -AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2010-10-28 WO disclosed
WO-2010122151-A1 3 -AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2010-10-28 WO disclosed
US-20080287475-A1 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer ASTRAZENECA AB (SE) 2008-11-20 US disclosed
US-4810797-A CATALYTIC CHLORINATION MAKHTESHIM CHEMICAL WORKS LTD. (IL) 1989-03-07 US disclosed